IMPACT OF PHARMACEUTICAL PROPOSALS IN MULTIDISCIPLINARY PROGRAMME FOR CLINICAL DECISION-MAKING IN IMMUNE-MEDIATED INFLAMMATORY DISEASES

M.D. GIL-SIERRA1, M.D.P. BRICEÑO CASADO2, C. MORENO-ROMAS3, M.A. BLANCO-CASTAÑO1, M.M. CUADROS-MARTINEZ3.
1HOSPITAL UNIVERSITARIO DE PUERTO REAL, PHARMACY, PUERTO REAL, SPAIN.
2HOSPITAL UNIVERSITARIO DE JEREZ DE LA FRONTERA, HOSPITAL PHARMACY, JEREZ DE LA FRONTERA CÁDIZ, SPAIN.
3HOSPITAL UNIVERSITARIO DE JEREZ DE LA FRONTERA, PHARMACY, JEREZ DE LA FRONTERA, SPAIN.

Section 4: Clinical Pharmacy Services

4CPS-030

BACKGROUND

Pharmaceutical proposals (PPs) in a multidisciplinary programme (MP) for immune-mediated inflammatory diseases could improve drug effectiveness and efficiency of clinical decision-making.

AIM

To evaluate the impact of PPs in a MP for the management of immune-mediated inflammatory dermatological and rheumatological diseases.

MATERIAL AND METHODS

MP during May 2021-September 2022

Patients

Patients with rheumatoid arthritis (RA), spondyloarthritis, psoriasis and psoriatic arthritis (PA) receiving etanercept or adalimumab for at least 6 months

Multidisciplinary programme (MP): internists, dermatologists, pharmacologists and pharmacists

- Bibliographic search on optimal therapeutic ranges (OTRs) of drugs
- PP protocol based on biochemical and clinical criteria.
- Pharmaceutical interviews (PIs) about disease evolution were conducted before PPs.

Recorded data: drugs, multidisciplinary meetings, biochemical test and PIs, drugs levels and anti-drug antibodies, type of accepted PPs and telematic PI answers.

RESULTS

- Total Patients: 645
- Drug distribution: 51.8% etanercept and 48.2% adalimumab
- Multidisciplinary meetings: 25
- Biochemical test and pharmaceutical interviews: 408
- Results of bibliographic search:
  → Adalimumab: OTRs of 5-8 μg/mL for RA and PA, 3.2-7 μg/mL for psoriasis and 4.6-12 μg/mL for spondyloarthritis.
  → Etanercept OTRs: 2-3 μg/mL for RA and spondyloarthritis, and 2-7 μg/mL for PA and psoriasis.
- Serum drug levels: outside the optimal therapeutic ranges in 72.9%
- Anti-drug antibodies: 18 patients.

Pharmaceutical proposals

PPs accepted: 305
Distribution:
  → Treatment optimisation: 183 (60%)
  → Drug switching: 52 (17%)
  → Unchanged therapy: 70 (23%)

Telematic PIs answers:
  → At 1 month after TO were: 81.8% "good course", 3.6% "mild disease" and 14.6% "poor course"
  → At 3 months were: 69.8% "good course", 5.7% "mild disease" and 24.5% "poor course".

CONCLUSION

Most of accepted PPs in our MP (DS and TO) can improve effectiveness and efficiency of treatments for immune-mediated inflammatory diseases in clinical decision-making. Almost three quarters of patients with TO presented good disease evolution.

CONTACT DATA

E-mail: mangilsie@yahoo.com